Clinical and Medical Case Reports

Fox Chase Cancer Center, Philadelphia, PA, USA

Publications

• Case Report   
  Response to Checkpoint Blockade in a Patient with Metastatic HER2-positive Breast Cancer
  Author(s): Melissa McShane, Lori J. Goldstein and Elias Obeid*
  
  The success of immunotherapy in breast cancer care is limited to the triple negative subtype. There are no current recommendations for the use of checkpoint inhibitors in HER2 positive disease; although the tumor biology in HER2-positive breast cancer demonstrates that the immune system has a potentially substantial contribution to the therapeutic effects of trastuzumab. Our group is currently conducting an investigator initiated clinical trial of safety and clinical activity for atezolizumab (a PDL-1 inhibitor) added to standard of care paclitaxel, trastuzumab and pertuzumab for first line treatment of patients with metastatic HER2-positive breast cancer (NCT03125928, PI: LJ Goldstein, co-PI: E Obeid). Our case report demonstrates the successful use of immunotherapy (in this case, pembrolizumab) and trastuzumab in a patient with metastatic HER2-positive breast.. Read More»
  DOI: 10.37421/2684-4915.2022.6.220

  Abstract HTML PDF